Loading
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Previous close
$0.3102
−$0.0298 · -8.76%
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
57
Fair Value
Sentiment
51
Mixed
Risk
73
High Risk
Momentum
21
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Day range
Current $0.3102
52-week range
Current $0.3102
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.73M USD | 1.23M USD | 775.3K USD | 306.39K USD | 90.04K USD |
| Gross profit | 1.73M USD | 1.23M USD | 775.3K USD | 306.39K USD | 90.04K USD |
| Research and development | 10.08M USD | 14.41M USD | 19.55M USD | 15.33M USD | 13.02M USD |
| Selling, general, and administrative | 13.38M USD | 13.64M USD | 16.92M USD | 16.4M USD | 14.83M USD |
| Operating expenses | 22.95M USD | 28.26M USD | 36.76M USD | 32.09M USD | 28.42M USD |
| Interest income | 600 USD | 9.95K USD | 93.32K USD | 125.27K USD | 2.73K USD |
| Interest expense | 2.49M USD | 340.36K USD | 221.62K USD | 173.09K USD | 155.8K USD |
| Depreciation and amortization | 1.22M USD | 1.34M USD | 1.41M USD | 1.19M USD | 1.15M USD |
| Operating income | −21.22M USD | −27.02M USD | −35.99M USD | −31.78M USD | −28.33M USD |
| Net income | −23.36M USD | −26.97M USD | −35.32M USD | −30.27M USD | −26.81M USD |
Company facts updated Sep 13, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
